State of the art treatment of chronic lymphocytic leukaemia

[Guest guest]

BlankState of the art treatment of chronic lymphocytic leukaemia.

M Hallek and N Pflug

Blood Rev, November 20, 2010; .

Klinik I f?r Innere Medizin, German CLL Study Group, University of Cologne,

Kerpener Strasse 62, 50937 K?ln, Germany; Center for Integrated Oncology (CIO)

K?ln Bonn, University of Cologne, Kerpener Strasse 62, 50937 K?ln, Germany;

Center of Excellence for Cellular Stress Responses in Aging-Associated Diseases

(CECAD), University of Cologne, Kerpener Strasse 62, 50937 K?ln, Germany.

The management of chronic lymphocytic leukaemia is currently undergoing profound

changes. Several drugs like bendamustine, alemtuzumab and rituximab have

recently been approved for CLL treatment by regulatory agencies. New and very

promising compounds like lenalidomide, ofatumumab, GA101, flavopiridol, or

ABT-263 are currently investigated in clinical trials and are likely to further

enlarge the therapeutic armamentarium in the next years. Latest results show

that chemoimmunotherapies like FCR (fludarabine, cyclophosphamide and rituximab)

may improve the life expectancy of CLL patients. This new paradigm will modify

the way of CLL management in a radical manner. Finally, the development of new

biological markers that describe distinct forms of CLL allows to enter the era

of personalized therapy similar to other malignancies.

PMID: 21095047